（图源：爱尔眼科供图） 当前世界，地缘冲突频繁、贸易保护主义甚嚣尘上，美国近期出台的所谓"对等关税"更是严重冲击全球经贸秩序，接续年初deepseek横空出世对全球AI产业 造成的震撼，重估中国资产价值的讨论更趋热烈。 当然，重估的标的不仅限于科技资产，随着生产效率提升带来的全社会利润率的改善，对中国资产的重估有望逐步扩散至其他板块。这其中，基本面坚实、 规模效应突出的各行业核心龙头将在这轮重估中凸显配置价值。 眼睛是最繁忙的器官，人类获取的外界信息约80%依赖视觉系统，但当代人群正面临日益严峻的眼健康危机。这种危机，涉及全年龄段人群的全生命期，尤 其是儿童青少年和老年群体的眼病呈快速上升趋势，眼科医疗需求随之递增。 国家疾控局监测数据显示，2022年我国儿童青少年总体近视率为51.9% (其中，小学36.7%，初中71.4%，高中81.2%)，近视人群高发化、低龄化、高度化的 形势严峻。叠加移动互联网加剧用眼强度，干眼症、高度近视带来眼疾病等治疗需求持续增长。 与此同时，据国家统计局数据，2024年末，我国60岁及以上老年人口已从2000年的1.26 亿人增加到了3.10亿人，老年人口占比从10.2%上升至 ...

门诊量手术量保持增长，加快"AI+眼科"应用布局。2024 年公司实现门诊量1,694.07 万人次，同比增长 12.14%；手术量129.47 万例，同比增长9.38%；公司基于深度学习和自然语言处理等数字技术，整合海 量眼科领域资源，自主研发的眼科垂直大模型 AierGPT 于 2024 年 9 月在世界近视眼大会上正式发布， 有效赋能眼健康科普、诊疗、培训及健康管理，助力打造"AI 数字眼科医生"。 公司持续分红，回购股份。公司拟向全体股东每 10 股派发现金红利1.6 元（含税）， 合计派发现金红 利14.87 亿元，占 2024 年度归属于上市公司股东净利润的 41.82%。同时，基于对公司未来发展前景的 预期，公司在 2023年至2024 年期间先后实施两期股份回购计划，通过二级市场累计回购31,363,178 股，占公司总股本的0.34%，成交总金额为 5.86 亿元。 事件：公司发布2024 年和2025Q1 业绩公告，2024 年公司实现营业总收入209.83 亿元，同比增长 3.02%；归母净利润35.56 亿元，同比增长5.87%，毛利率降低2.67pct 至48.12%。2025Q1 ...

Group 1: Company Insights - The company achieved a revenue of 11.36 billion yuan in Q1 2025, representing a year-on-year increase of 22.47% and a quarter-on-quarter increase of 29.43% [5] - The net profit attributable to shareholders for Q1 2025 was 2.83 billion yuan, up 11.82% year-on-year, while the non-recurring net profit was 2.75 billion yuan, reflecting a year-on-year increase of 38.71% [5] - The newly launched game "Wanjian Changsheng" contributed significantly to revenue and profit growth in Q1 2025, with a revenue of 3.63 billion yuan [6] Group 2: Industry Trends - The eye care industry is experiencing a slowdown in growth, with the company managing to maintain revenue growth despite external challenges, achieving a revenue of 60 billion yuan in Q1 2025, up 16% year-on-year [8][9] - The company is expanding its international presence, with significant revenue contributions from Europe and Southeast Asia, achieving a total revenue of 210 billion yuan in 2024 [10] - The chemical industry is seeing a substantial increase in revenue, with the company reporting a revenue of 8.59 billion yuan in Q1 2025, a year-on-year increase of 91.68% [12][15] Group 3: Financial Performance - The company reported a net profit of 0.67 billion yuan in Q1 2025, which is a 10.46% increase year-on-year and a remarkable 902.93% increase quarter-on-quarter [12][15] - The net profit margin for the company improved significantly, with a sales net profit margin of 10.80% in Q1 2025, reflecting a year-on-year decrease of 3.1 percentage points [12] - The company is expected to see continued revenue growth, with projected revenues of 41.27 billion yuan, 48.48 billion yuan, and 55.70 billion yuan for 2025, 2026, and 2027 respectively [17]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][7][8] Core Insights - The company reported a revenue of 21 billion yuan in 2024, representing a 3% year-on-year increase, and a net profit of 3.56 billion yuan, up 6% year-on-year. In Q1 2025, the company achieved a revenue of 6 billion yuan, a 16% increase, and a net profit of 1.05 billion yuan, a 17% increase [2][4] - The company is focusing on the "AI + Ophthalmology" strategy, enhancing its digital capabilities and expanding its international presence, particularly in Europe [4][5] - The company has maintained growth in patient volume despite a slowing industry, with outpatient visits increasing by 12% and surgeries by 9% in 2024 [4][5] Financial Performance - The company is projected to achieve revenues of 23.75 billion yuan, 26.84 billion yuan, and 30.34 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 13.2%, 13.0%, and 13.0% [6][7] - The net profit is expected to reach 4.17 billion yuan, 4.88 billion yuan, and 5.71 billion yuan for the same years, with growth rates of 17.2%, 17.1%, and 17.0% respectively [6][7] - The company maintains a strong return on equity (ROE) forecasted to increase from 17% in 2024 to 20% in 2027 [6][7][8] Market Performance - The company's stock has shown a performance of -2.7% over the last month, 6.5% over the last three months, and 5.3% over the last year, outperforming the CSI 300 index in the three-month and one-year periods [3][4] - The current stock price is 13.13 yuan, with a 52-week price range of 9.05 to 19.09 yuan [3][4] Strategic Initiatives - The company is advancing its "1+8+N" layout and international strategy, with a total of 352 domestic hospitals and 163 overseas ophthalmology centers and clinics as of December 31, 2024 [4][5] - The introduction of AI technologies, such as AierGPT and Eyecho, aims to enhance patient care and operational efficiency [4][5]